Overview

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Status:
Active, not recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy acalabrutinib and ACP 319 in B-cell malignancies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Acerta Pharma BV
Collaborator:
AstraZeneca
Treatments:
Acalabrutinib